Research Article

The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation

Table 1

Patients characteristics, CML stage and IM response. F: Female, M: Male, Δsis: Diagnosis, CP: chronic phase, BC: blastic crisis, AP: accelerated phase, IM: imatinib, Mol: molecular, Hem: hematologic, Cyt: cytogenetic, Hep: hepatic, MMR: major molecular reponse, NR: no reponse.

Case numberSexAge (years) sis1st line therapyType of relapse at IM therapyIM dose (mg/d)Maximum IM reponseTime to acheive MMR (month)ToxicityCurrent RT-PCR status

1M28CML (CP)IMMol400MMR3.7NoNegative
2F44CML (CP)IMCyt400MMR9.2NoPositive
3M50CML (CP)3XHem400MMR3NoNegative
4F47CML (CP)1XHem400MMR6HemPositive
5M55CML (BC)IMHem600NRHem
6F48CML (CP)IMMol400MMR2HepPositive
7F45CML (AP)IMHem600MMR9.5HemPositive